The research leading to ADRI’s upcoming clinical trial has been recognised by the award of one of two best poster prizes at the recent WIN Symposium 2014 in Paris. The study describes the translational research leading to the new microRNA-based treatment approach for malignant pleural mesothelioma and non-small cell lung…Read More
Australian scientists, inventors and surgeons worked together in ground-breaking research that has lead to the discovery of a way to slow down the growth of deadly asbestos-related cancer malignant pleural mesothelioma. The break-through underpins a clinical trial due to start in six weeks.
More than 10,000 Australians have died since the early 1980s, with more than 25,000 expected to die over the next four decades, because of mesothelioma, an asbestos-related cancer. The cancer can take up to 40 years to develop.Read More
This year’s finals of the Concord Repatriation General Hospital Early Career Research Awards were held on 22nd and 29th of October at the ANZAC Research Institute. These yearly research prizes are co-sponsored by Concord Hospital and the ANZAC Research Institute and awarded to early career researchers who primarily undertake their work on…Read More
Asbestos is the generic term used for a number of silicate minerals with fibrous crystalline structures. For more than 4,500 years naturally occurring fibrous minerals have been used by humans for their flexibility, strength, chemical inertness and insulation qualities. The Romans used asbestos for its flame-retardant and insulation properties by…Read More
Professor Ken Takahashi is the Director of the Asbestos Diseases Research Institute (ADRI), University of Sydney. After graduating from the School of Medicine, Keio University (Japan) and accomplishing clinical residency, he moved to the University of Occupational and Environmental Health, Japan. There he studied and worked for 31 years including…Read More